Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 32 people across three groups, all of whom had sinusitis. The three groups were: those using a Fluticasone nasal spray (10 people), those using a Budesonide liquid rinse while keeping their head upright (10 people), and those using a Budesonide liquid rinse while leaning their head forward (12 people). The trial measured two things: first, a symptom questionnaire called the SNOT-22, where a higher score means a person reported feeling more unwell (scored out of 110); and second, how the inside of the nose looked under a small camera (called nasal endoscopy), rated on a scale where a higher score means the nose appeared more severely affected. Not all participants finished the study — 8, 8, and 7 people completed it in each group respectively. The reported data shows the following SNOT-22 scores at the end of the study: the Fluticasone nasal spray group had an average score of 31.5, the Budesonide head-upright group had an average score of 10.29, and the Budesonide head-forward group had an average score of 15.88. For the nasal endoscopy camera scores, the reported data shows the Fluticasone group averaged 2.69, the Budesonide head-upright group averaged 0.50, and the Budesonide head-forward group averaged 1.13. These are the numbers as submitted; no further breakdown of the results, such as scores at the start of the trial for comparison, was included in the reported data on ClinicalTrials.gov. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 26679480) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Chronic Rhinosinusitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are an adult who has had a type of sinus surgery (called FESS) to treat chronic sinusitis with nasal polyps, and your surgery took place within the study's timeframe.
Who may not be able to join:
- You are under 18 years old.
- You are currently taking oral steroids (such as prednisone) at a dose higher than 10 mg per day.
- You are taking certain medications that speed up how your body processes steroids — including Dilantin (phenytoin), rifampin, amphetamines, or lithium.
- You are taking certain medications that slow down how your body processes steroids — including ketoconazole, amphotericin B, bupropion, or fluoroquinolones (a type of antibiotic).
- You have a known allergy or sensitivity to steroid medications.
- You have a personal history of Wegener's Granulomatosis (a rare inflammatory condition) or another autoimmune disease that affects the nose and sinuses.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
SNOT-22 Scores
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.